Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UHRF2 antisense RNA 1 (UHRF2-AS1) is a long non-coding RNA gene transcribed antisense to the UHRF2 (ubiquitin-like with PHD and RING finger domains 2) gene locus. As with many antisense RNAs, UHRF2-AS1 is thought to participate in the regulation of its sense gene (UHRF2) or associated pathways through mechanisms such as chromatin modification, transcriptional interference, or epigenetic regulation. There is emerging evidence that altered expression of UHRF2-AS1 may be associated with the development or progression of certain cancers, but its precise functional roles remain to be fully clarified. UHRF2-AS1 is not a protein, receptor, or enzyme, and is not currently a direct target of any approved drugs.
Not applicable for direct drugs. In theory, if targeted by ASOs or RNAi, the mechanism would involve RNA degradation or transcriptional inhibition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on UHRF2 antisense RNA 1 (UHRF2-AS1).